Chinese biotech firm offers unproven iPS cell treatment

08/5/2008 | InformationWeek

China-based Beike Biotechnology is using a promising but untested therapy involving induced pluripotent stem cells to treat hundreds of patients -- many from Western countries -- suffering from diseases deemed incurable, such as cerebral palsy and muscular dystrophy. The company's technology, which uses a combination of umbilical-cord cells and stem cells extracted from patients, "may someday create the conditions for effective clinical treatments and industrial scale production of iPS cells," a U.S. researcher said.

View Full Article in:

InformationWeek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ